Acetyl Hexapeptide-30_Dosage, benefits & legal status
Also known as Inyline, acetyl hexapeptide 30
A wrinkle peptide with no public sequence, by design.
Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is Acetyl Hexapeptide-30?
Plain language first. The technical label stays, but it never stands alone.Overview
This is a wrinkle-relaxing peptide of the Botox-alternative kind, and it is unusual on this site for a simple reason: nobody outside the company knows what it is. Its sequence has never been published, and that is not an oversight we are inferring. A rival company's patent lists this ingredient in a comparison table, prints the sequence of the better-known Argireline in full, and against this one writes that the sequence is not published. The claimed mechanism is interesting: where Argireline and its relatives work inside the nerve ending to reduce the signal being sent, this one is said to work on the muscle side, blocking the muscle's own machinery for building receptors. The trouble with that claim is depth. The peptide would have to cross skin and reach a structure below the dermis, and the only peptide in this class with published permeability data cannot even reach the living epidermis.
Acetyl Hexapeptide-30 is the INCI name for an acetylated six-residue peptide sold under the trade name Inyline for expression lines. Its sequence has never been published. It is marketed as a competitive antagonist of muscle-specific kinase at the agrin binding site, placing it post-synaptically, on the muscle side of the neuromuscular junction, unlike the three other expression-line peptides on this site. The only functional data is one in vitro assay in differentiated mouse myotubes, reporting 72% inhibition of acetylcholine receptor clustering at 100 micromolar. No binding assay, no receptor phosphorylation measurement and no permeation study exists, and the developer's own patent declines to claim the named target.
What it's used for
Used in topical skincare for expression lines, especially around the eyes. A cosmetic ingredient, not a drug, and not an alternative to an injected neuromodulator.
How does Acetyl Hexapeptide-30 work?
What it does in the body, and where.Four peptides on this site are sold for expression lines, and all four come from the same ingredient developer. Its own framing is the cleanest way to separate them: three act before the nerve signal is released, and one acts after. This is the one.
- 01How a nerve tells a muscle to contractA nerve ending releases acetylcholine, and it crosses a tiny gap and binds receptors on the muscle membrane. Two different places to interfere, then: the releasing side or the receiving side. Injected neuromodulators work on the releasing side, cutting the protein machinery that lets vesicles fuse.
- 02The three pre-synaptic peptides, for contrastArgireline, six residues, mimics the N-terminus of SNAP-25 and competes with it for a place in the complex that releases vesicles. SNAP-8 is the same strategy with two residues added. Leuphasyl works through the enkephalin receptor to damp the signal. All three are inside or at the nerve ending, and all three have public sequences.
- 03This one is on the muscle sideThe claim is that it blocks the assembly of acetylcholine receptors into clusters on the muscle membrane, by competing at the binding site of agrin, the nerve-derived signal that organizes them. If true, that is a different point of attack from everything else in the class, and it is the one thing about this ingredient that is clearly distinctive.
- 04What was measured, and what was notOne assay: mouse myotubes, receptor clusters induced by a recombinant agrin fragment and visualized by fluorescence microscopy, with 72% inhibition at 100 micromolar, described as comparable to the positive control. In that assay agrin is the stimulus, not a demonstrated target. There is no binding assay, no measurement of the kinase being switched on or off, and no competition data against agrin. The named molecular target comes from molecular modeling plus a downstream phenotype, and the developer's own patent claims only the inhibition of clustering while confining agrin and that kinase to its background section describing normal physiology. The supplier's marketing names a target that the developer's patent declines to claim.
- 05The depth problem, the strongest point on this pageA 2025 peer-reviewed review of Argireline, the far better studied member of this class, concludes that transdermal delivery sufficient to relax muscle is likely impossible. Its permeability data: with 10% Argireline over 24 hours, 0.22% penetrated the outer dead layer, 99.7% washed off, and none reached the receptor solution, with tape stripping finding the highest concentration in the outermost layer and falling toward the living epidermis. This peptide is a comparably sized charged hydrophilic acetylated hexapeptide, and its claimed target is deeper still, below the dermis on the muscle side of the junction rather than at the nerve terminal. No permeation data for it exists at all.
What else is it used for?
Each group carries its own evidence level.Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
The sequence, and who says it is not published
none- No dataThe sequence has never been published. A competitor's US patent lists this ingredient in a comparison table, prints Argireline's sequence in full, and marks this one as not published.
- RegulatoryNo FDA substance registration record and no CAS number exist, and the standard cosmetic ingredient reference defines the ingredient circularly.
- No dataThe origin patent discloses a family of candidate acetylated hexapeptides but never names this ingredient, so the identity cannot be pinned even from the patent.
- lab-analysisThe commercial secrecy is also a gray-market immunity: with no public sequence and no CAS, there is nothing for a supplier of raw powder to copy, while Argireline is sold as powder everywhere.
The mechanism, and how much of it is demonstrated
Early research- Lab studyThe one functional result is 72% inhibition of acetylcholine receptor clustering at 100 micromolar in differentiated mouse myotubes, with replicate counts, duration and positive-control concentration not stated.
- No dataThe named molecular target is not demonstrated anywhere: no binding assay, no kinase phosphorylation measurement, no receptor phosphorylation data and no agrin competition data. It rests on molecular modeling plus a downstream phenotype.
- No dataThe developer's own patent claims only inhibition of clustering and confines the named kinase to its background section. The supplier's marketing names a target the patent declines to claim.
- lab-analysisWhat is clearly true: among the four expression-line peptides on this site it is the only post-synaptic one. The developer's own trade framing is three pre-synaptic peptides and one post-synaptic.
Numbers that do not reconcile
none- No dataThe patent's own exemplified peptides achieved 20.8%, 21.5%, 23.7% and 24.5% inhibition in a table whose threshold for inclusion was above 20%. The brochure claims 72%.
- No dataEither the marketed peptide is not among the patent's tabulated compounds, or the two figures come from assays that cannot be compared. Neither possibility flatters the marketing.
- No dataThe patent example's 44.7% is a relative improvement against placebo while the brochure's 14.9% is an absolute change, so the two cannot be cross-checked against each other.
The delivery problem, shared by the whole class
none- ReviewA 2025 peer-reviewed review of Argireline concludes that transdermal delivery sufficient to relax muscle is likely impossible.
- Lab studyIts data: 10% Argireline over 24 hours gave 0.22% stratum corneum penetration, 99.7% washed off, and nothing reaching the receptor solution.
- No dataThis peptide's claimed target is deeper than Argireline's, on the muscle side of the junction rather than in the nerve terminal, and it has no permeation data at all.
The 14.9% wrinkle-depth figure is quoted as though it were a clinical result. It comes from a 20-woman supplier panel with no stated placebo or vehicle control and no p-value, at 25 parts per million of peptide, and the supplier's current page repeats it with no design, no sample size and no method at all. The 72% laboratory figure is quoted as potency, and it sits awkwardly beside the developer's own patent, whose exemplified peptides of this type reached 20.8 to 24.5% in the same kind of assay. The stated molecular target is presented as established; no binding assay, no phosphorylation measurement and no competition data exists for it, and the developer's own patent claims only the downstream effect. There is one correction in the ingredient's favor, too: it is sometimes described as having no controlled human data whatsoever, and a vehicle-controlled split-eye experiment does exist inside the origin patent. It just names no peptide and states no concentration, so it cannot be attributed to this ingredient. Underneath all of it is the one problem nobody markets around: the claimed target is below the dermis, and the best-studied peptide in this class does not reach the living epidermis.
The published record
0
Papers about Acetyl Hexapeptide-30
Searched: acetyl hexapeptide-30, Inyline.
Left out: acetyl hexapeptide-8 (Argireline, with its own slug, and the single most important rejection here. Same developer, same purpose, PRE-synaptic rather than post-synaptic, public sequence Ac-EEMQRR-NH2, public CAS, and an enormous share of the cosmetic-peptide literature. A competitor's patent prints Argireline's sequence in full while marking THIS one's as not published); Argireline (the trade name for that different peptide, returning commerce and review pages that are not about this ingredient); acetyl octapeptide-3 (SNAP-8, with its own slug, a two-residue elongation of Argireline and also pre-synaptic); pentapeptide-18 (Leuphasyl, with its own slug, the third pre-synaptic peptide in the same family, acting through the enkephalin receptor); MuSK (the claimed molecular target, a major neuromuscular-junction term. The claim is NOT demonstrated for this peptide and the developer's own patent declines to make it); agrin (the assay STIMULUS, not a demonstrated target, with a large neuroscience literature of its own); botulinum (the injected comparator people reach for, with an enormous unrelated literature).
Europe PMC was searched on 9 November 2026 for these terms and returned nothing.
Counted from Europe PMC indexing, not read by a person.
At a glance
Four things to know about Acetyl Hexapeptide-30
Evidence
Cosmetic
Category
Skin and cosmetic
Common vial
Varies
Half-life
Not measured, and not the right question
How much, and do you cycle it?
The range, and whether you take breaks.Serum, per product, daily. Not cycled Community practice
Used daily as part of a routine. The effect depends on continued use and returns to baseline when you stop, so there is nothing to cycle off.
Not measured, and not the right questionNo figure
This is a topical cosmetic ingredient. A blood half-life measures how fast something is cleared from the bloodstream, and nothing here is meant to reach the bloodstream. The question that matters for a topical peptide is whether any of it crosses the outer layer of skin at all, and for this ingredient no permeation study exists. For this ingredient that gap is the whole story, because its claimed target lies on the muscle side of the nerve junction, below the dermis.
You can compare this against the whole library to see where it sits.
What does it cost?
Typical dose and cost, in plain numbers.Acetyl Hexapeptide-30 is not injected in the forms covered here
It is taken on the skin (topical). Applied as a topical product at the concentration the manufacturer sets. There is no injected dose. The supplier sells it as a solution that is 0.05% active, recommended at 5% in a finished formula, so the tested cream contained 0.0025% peptide, or 25 parts per million.
How do you store it?
Before mixing, and after.Room temperature, out of light. Cap it tight after each use.
Acetyl Hexapeptide-30 ships as a cream, gel, or serum. Keep it at room temperature away from sun and heat unless the label says otherwise. Refrigerating an emulsion can split the texture. Watch for color, smell, or separation changes and stop using it if any appear.
What are the side effects and cautions?
Known cautions and warnings for this compound.Who should avoid it
- Expecting an injected-neuromodulator effect, since the one peptide in this class with published permeability data reaches only the outer dead layer of skin
- Quoting the 72% figure as comparable to the patent's own numbers, because the patent's exemplified peptides reached 20.8 to 24.5% in the same kind of assay
- Reading the stated molecular target as demonstrated, since the developer's own patent claims only the downstream effect and confines that target to its background section
Stop and get help
- Redness, burning or swelling that persists after use, as with any new topical
- Any irritation around the eyes, where these products are usually applied
Common effects
- Nothing beyond ordinary topical tolerability has been reported.
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is Acetyl Hexapeptide-30 approved?
And where the numbers on this page come from.Not as a medicine. Acetyl Hexapeptide-30 is sold without a prescription as a cosmetic ingredient, which is a different thing from being approved as a drug.
- Approval statusCosmeticSold without a prescription as an ingredient in cosmetics, such as skincare and hair products. The FDA does not approve cosmetics before they are sold, and being easy to buy says nothing about whether it works.
- RouteOn the skin (topical)
- Checked5 November 2026
- DoseFrom the concentration range manufacturers formulate at. This is a product strength, not a dose set by a regulator or a trial.
- Vial sizeFrom what vendors typically list; not a recommendation.
- SourcesInternational Journal of Molecular Sciences, skin permeability and efficacy of Acetyl Hexapeptide-8European patent EP2456457B1, the origin patent and its own numbersSupplier product page and trade article, the 14.9% figureTrade article, a novel post-synaptic strategy against expression linesTrade article on the developer's four expression-line peptides
What has happened recently
A cosmetic ingredient, so there is no approval to have. Its identity cannot be pinned from any public record. An exact-field query of the FDA substance registration database returns zero records, so there is no UNII and no CAS number, and the standard cosmetic ingredient reference defines the ingredient circularly. The origin patent discloses a family of candidate acetylated hexapeptides but never names this ingredient, so even the patent does not tell a reader which one it is. The clearest evidence that the secrecy is deliberate comes from outside the company: a US patent filed by a different firm lists this ingredient in a comparison table, prints Argireline's sequence in full, and records this one's sequence as not published. One consequence is worth stating plainly, because it cuts in the ingredient's favor: Argireline has a public sequence and a public CAS number and is sold as raw powder everywhere, while this peptide has no gray market at all, because there is nothing to copy.
You can compare this against the whole library, or read how to check a seller.
What else is like Acetyl Hexapeptide-30?
Others in Skin and cosmetic, side by side.If you're weighing Acetyl Hexapeptide-30, it's worth reading Acetyl Hexapeptide-37 (Diffuporine), Acetyl Hexapeptide-38 (Adifyline), and Acetyl Tetrapeptide-11 in the same class.
A wrinkle peptide with no public sequence, by design.
- Dose
- Serum, per product
- How often
- Daily
A six-residue Lipotec peptide sold as Diffuporine, said to make skin cells produce more aquaporin-3 water channels. Every efficacy figure comes from the supplier, with methods undisclosed.
- Dose
- 2% Diffuporine solution in a cream or serum (supplier)
- How often
- Per product; no tested schedule published
A topical sold on the idea that it grows fat cells.
- Dose
- Set by the finished product
- How often
- As directed by the product
A topical cosmetic peptide sold as Syniorage, claimed to firm mature skin by raising syndecan-1 and collagen XVII.
- Dose
- Serum or cream, per product
- How often
- Daily
Guides for this compound
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
- International Journal of Molecular Sciences, skin permeability and efficacy of Acetyl Hexapeptide-8(2025)Volume 26, article 5722. Not about this peptide, and the most important source on this page for that reason. Reviewing Argireline, the best-studied member of the same class, it concludes that transdermal delivery sufficient to produce a muscle-relaxing effect is likely impossible. The underlying permeability data: 10% Argireline over 24 hours gave 0.22% penetration of the stratum corneum, 99.7% removed by washing, and nothing reaching the receptor solution, with tape stripping showing concentration falling inward from the outer surface. This peptide is comparably sized, charged and hydrophilic, its claimed target is deeper, and it has no permeation data of its own.
- European patent EP2456457B1, the origin patent and its own numbers(2015)Two things in this document matter. Its Table 2 reports what the patent's own exemplified acetylated hexapeptides achieved against receptor clustering: 20.8%, 21.5%, 23.7% and 24.5%, the first three at 10 micromolar and the fourth at 100 micromolar, in a table whose inclusion threshold is above 20% inhibition. The commercial brochure claims 72% at 100 micromolar. Either the marketed peptide is not among the tabulated compounds, or the two numbers come from assays that cannot be compared. The patent also contains the only vehicle-controlled human experiment in the entire record for this ingredient: 20 volunteers, mean age 45, active composition on one eye and an identical placebo cream without the peptide on the other, twice daily for one month, measured by optical 3D wrinkle depth, reporting a 44.7% increase in average wrinkle depth reduction against placebo. It cannot be credited to this ingredient, because the example does not name which peptide was used and states no concentration, and a patent example is unpublished, unrefereed and written by the developer to support patentability. It is listed here so that a reader who finds the patent does not conclude the site missed it.
- Supplier product page and trade article, the 14.9% figure(2026)The number quoted everywhere. Twenty female volunteers aged 41 to 50, cream containing 5% of the supplier solution applied to the crow's feet area twice daily for 28 days, wrinkle depth by optical 3D at day 0 and day 28, result a 14.9% decrease in mean wrinkle depth with a positive effect in 90% of volunteers, analyzed by descriptive statistics and a rank test. Neither source states a placebo or vehicle control, and no p-value is reported. The arithmetic worth carrying: the solution is 0.05% active used at 5%, so the tested cream held 0.0025% peptide, 25 parts per million. The current supplier page repeats the 14.9% figure with no design, no sample size and no method.
- Trade article, a novel post-synaptic strategy against expression lines(2011)The developer's own announcement of the ingredient, and the second of the two places the 14.9% panel figure appears. Like the product page, it states no placebo or vehicle control and reports no p-value.
- Trade article on the developer's four expression-line peptides(2026)The developer's own framing of how its four expression-line peptides divide: three pre-synaptic and one post-synaptic. That split is the cleanest verified statement of what makes this ingredient different from Argireline, SNAP-8 and Leuphasyl, all three of which are also covered on this site.